Posts Tagged ‘Provenge’

NEW PROSTATE CANCER INFOLINK: Long-awaited advanced prostate cancer drug Provenge is a step closer to being available with news the manufacturing company has completed its full application to the FDA. READ MORE>

Read Full Post »

WALL STREET JOURNAL: Dendreon Corp expects to file for marketing approval for advanced prostate cancer immunotherapy treatment Provenge in mid-November and hopes to get final FDA approval in the middle of next year. READ MORE>

NEW PROSTATE CANCER INFOLINK: It is worth remembering that Provenge is not a “drug” in any normal sense of the term. READ MORE>

Provenge is strictly a form of individual cell-based immunotherapy in which cells from the patient’s own body are extracted, modified, and then re-infused back into the patient.

Every single dose of Provenge therefore has to be individually created.

PROSTABLOG NZ: The pressure on NZ’s drug approval organisation, Pharmac, to fast-track Provenge to Kiwi patients is shaping to be another Herceptin debate.

In that case, it seems only a very loud and effective campaign by sufferers succeeded in getting the expensive breast cancer treatment past Pharmac’s drug subsidisation process.

If Provenge has to be individually manufactured for each patient, you can bet the doses will cost thousands of dollars.

Pharmac may be spared the dilemma beyond next year, since it seems the manufacturer will not be able to fulfill the demand in the US, let alone other countries.

Read Full Post »

PROSTABLOG NZ: When global mainstream media reported the recent (partial) success of Dendreon drug company getting FDA approval for its new immunotherapy prostate cancer drug, Provenge, they didn’t mention how makers of a now-discredited rival drug may have delayed its path to chemist shops.

An “alternative” market investors’ website called Market Rap.com has just published a story by a former Wall Street Journal journalist that purports to reveal a murky background to what might be called – if it’s all, even partly, true – one of America’s biggest drug scandals.

It involves the US prostate Cancer Foundation (no relation to NZ’s) and its ubiquitous chairman, Michael Milken, who featured recently on the Larry King Live special about prostate cancer.

If you’ve got lots of time, READ MORE>

Read Full Post »

PUGET SOUND BUSINESS JOURNAL: The US drug company that is about to produce the world’s most promising immuno-therapy prostate cancer treatment – Provenge – has reported a second-quarter loss of $126.7 million. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFOLINK: A screening test that distinguishes between indolent and harmful prostate cancer, better drugs, and more immuno-therapy treatments (like Provenge) for advanced cancer – these are priorities the prostate community has chosen in a poll. READ MORE>

Read Full Post »

XCONOMY SEATTLE: Dendreon’s immune-stimulating therapy for prostate cancer, called Provenge, was able to improve median survival time by 4.1 months, and lowered the risk of death by 22.5 percent, according to long-awaited clinical trial results presented at the American Urological Association annual meeting today. READ MORE> and HERE>

Read Full Post »

US COMPETITIVE ENTERPRISE INSTITUTE: RESEARCHERS announced very favourable results for the drug Provenge at this week’s meeting of the American Association of Cancer Research. But that only highlights the shortcomings of the Food and Drug Administration, which has refused to approve the drug, despite previous studies indicating its safety and effectiveness. READ MORE>

Read Full Post »

« Newer Posts